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Abstract 
Review on ARID1A, with data on DNA/RNA, on 
the protein encoded and where the gene is 
implicated. 
Identity 
Other names: B120, BAF250, BAF250a, BM029, 
C1orf4, ELD, MRD14, OSA1, P270, SMARCF1, 
hELD, hOSA1 
HGNC (Hugo): ARID1A 
Location: 1p36.11 
Local order: Gene orientation: telomere-3' 
ARID1A 5'-centromere. 
DNA/RNA 
Description 
ARID1A gene is encoded by 20 exons spanning 
86,08 Mb. 
Transcription 
Human ARID1A has 2 transcript variants. The long 
variant (isoform 1) transcribed into 8585 bp 
mRNA, the coding sequence is from 374 bp - 7231 
bp.  
The short variant (isoform 2) transcribed into 7934 
bp mRNA, the coding sequence is from 374 bp - 
6580 bp. Isoform 2 has a shorter exon 18 compared 
to isoform 1. 
Protein 
Note 
The longer isoform of ARID1A consists of 2285 
amino acids (pI: 6.24), with predicted molecular 
mass of 242,04 kDa. The shorter isoform of 
ARID1A consists of 2068 amino acids (pI: 6.08), 
with predicted molecular mass of 218,33 kDa. Both 
isoforms contain a single "ARID" DNA binding 
domain and four "LXXLL" nuclear receptor 
coactivator motifs. 
 
DNA organization of ARID1A. 
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ARID1A protein. 
 
Description 
ARID1A is a member of the SWI/SNF family that 
can regulate genes transcription by chromatin 
structure alteration through its helicase and ATPase 
activities. The encoded ARID1A nuclear protein is 
part of the BRG/BRM chromatin remodeling 
complex that has been shown to play an integral 
role in controlling gene expression. 
Expression 
Ubiquitously expressed in various normal tissues, 
with the highest expression seen in brain, blood and 
female tissues. 
Localisation 
Mainly located at cell nucleus but not at nucleolus. 
Function 
ARID1A contains a conserved DNA-binding 
domain (ARID) that could be important for its 
function and can specifically bind an AT-rich DNA 
sequence. ARID1A is part of the large ATP-
dependent chromatin remodeling complex 
SNF/SWI, which is required for transcriptional 
activation of genes. Changes in this SNF/SWI 
complex has been implicated in many cellular 
processes, including development, differentiation, 
proliferation, DNA repair, and tumor suppression. 
ARID1A has been reported to act as tumor 
suppressor in gynecological cancers (Guan et al., 
2011b). Molecular studies using over-expression 
and RNAi silencing models have demonstrated that 
ARID1A negatively regulates cellular proliferation 
and tumorigenicity. This negative regulation is 
achieved through molecular collaboration between 
ARID1A/BRG1 and p53, to regulate tumor-
inhibiting p53-downstream target genes such as 
CDKN1A and SMAD3. Using mutational studies, 
Guan et al. (2012) have further confirmed ARID1A 
role as tumor suppressor, with all of the in-frame 
indel mutants have lost their ability to inhibit 
cellular proliferation. 
Mutations 
Germinal 
ARID1A mutations have been implicated in Coffin-
Siris syndrome, a rare genetic disorder that causes 
developmental delay and abnormities in 5th fingers 
or toes (Tsurusaki et al., 2012; Santen et al., 2013; 
Wieczorek et al., 2013). 
Somatic 
ARID1A is located at chromosome 1p that is 
frequently deleted in tumours. ARID1A sequence 
mutations, deletions, and rearrangements were 
identified in ovarian, kidney, breast, lung, 
pancreatic and stomach cancer. 
Implicated in 
Ovarian clear cell carcinoma 
Oncogenesis 
ARID1A somatic mutations were identified in 57% 
of the 42 ovarian clear cell carcinomas (Jones et al., 
2010). Maeda et al. (2010) has demonstrated that 
ARID1a genetic mutations resulted in loss of 
ARID1A protein expression in 59% of the 149 
ovarian clear cell carcinomas.  
Study with a larger cohort of 210 patient samples 
has also demonstrated that ARID1A somatic 
mutation were found in 46% of patients with 
ovarian clear-cell carcinoma and 30% of patients 
ovarian endometrioid carcinoma (Wiegand et al., 
2010). 
ARID1A inactivation by ARID1A mutations has 
been suggested as an early molecular event that can 
lead to tumor progression from benign ovarian 
endometroid cysts into an aggressive ovarian clear 
cell and endometrioid carcinoma (Ayhan et al., 
2012). 
Uterine endometroid carcinoma 
Oncogenesis 
ARID1A mutations were observed in 40% of 
uterine endometrioid carcinoma with none 
presented in uterine serous carcinomas (Guan et al., 
2011a). All of the mutations in endometrioid 
carcinomas were the nonsense or insertion/deletion 
types (Guan et al., 2011a) and expected to result in 
complete loss or clonal loss of ARID1A expression. 
Immunostaining confirmed the relatively significant 
frequency of loss of ARID1A protein expression 
with 25-26% and 44% in uterine low-grade and 
high-grade endometrioid carcinomas, respectively 
(Guan et al., 2011a; Werner et al., 2013; Mao et al., 
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2013). Hence, mutation-related loss of ARID1A 
expression has also been hypothesized as an early 
event and played an important role in tumor 
progression of uterine endometrioid carcinoma 
(Ayhan et al., 2012; Werner et al., 2013; Mao et al., 
2013). 
Cervical cancer 
Oncogenesis 
Loss of ARID1A protein expression was observed 
in 31% (14/45) of cervical 
adenocarcinomas/adenosquamous carcinomas with 
no correlation to any clinicopathological features 
(Katagiri et al., 2012). Later studies using a large 
series of cervical cancer tissue specimens, ARID1A 
expression was found to be significantly decreased 
in cervical cancer tissues than in non-adjacent 
normal cervical epithelial tissues (Cho et al., 2013). 
The decrease of ARID1A expression was also 
found to be associated with transition from normal 
cells to cervical carcinoma and a more aggressive 
tumor phenotype (Cho et al., 2013). Overall 
survival was also found to be reduced in cervical 
cancer patients with loss of ARID1A (Cho et al., 
2013). 
Breast cancer 
Oncogenesis 
Low ARID1A expression was observed in 56% 
(63/112) of the breast cancers samples and was 
significantly associated with advanced tumor stage, 
higher P53 expression, increase Ki-67 and triple 
negative (ER-/PR-/Her-2-) molecular subtype 
(Zhang et al., 2012; Mamo et al., 2012). Low 
ARID1A expression was a predictor of poor overall 
survival of breast cancer patients (Zhang et al., 
2012; Mamo et al., 2012). Breast cancer also 
exhibited a low rate (3-4%) of ARID1A mutations 
(Jones et al., 2010; Cornen et al., 2012). 
Gastric cancer 
Oncogenesis 
Inactivating mutation of ARID1A has also been 
identified gastric cancer (Wang et al., 2011; Abe et 
al., 2012; Zhang et al., 2012). Loss of ARID1A 
expression has been correlated with increasing 
depth of tumor infiltration, higher tumor grade, and 
poor overall patient survival (Abe et al., 2012; 
Wang et al., 2012). Moreover, ARID1A expression 
has been shown as an independent prognostic factor 
of overall survival in multiple studies (Abe et al., 
2012; Wang et al., 2012). 
Coffin-Siris syndrome 
Prognosis 
Hepatoblastoma and multiple congenital anomalies. 
Oncogenesis 
ARID1A mutations in individual with Coffin-Siris 
syndrome lead to a truncation and nonfunctional 
ARID1A protein (Tsurusaki et al., 2012; Santen et 
al., 2013; Wieczorek et al., 2013). As a result, 
affected individuals developed abnormalities, such 
as missing the fifth fingers or toes and coarse 
characteristic of facial features. Moreover, cancer 
was not detected in any of the individual with 
ARID1A mutation, reported in this study. 
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